期刊文献+

科素亚联合卡托普利治疗心衰临床观察 被引量:1

下载PDF
导出
摘要 目的:通过对心衰患者联合使用科素亚及卡托普利,观察疗效。方法:将60例心衰患者随机分为两组,治疗组服科素亚25mg,每日1次,卡托普利12.5-50mg,每日3次;对照组服卡托普利12.5-25mg,每日3次。疗程均为8周。结果:治疗组心功能改善I级及以上者2 6例,占86.7%,对照组心功能改善I级及以上者21例,占70%,治疗组明显优于对照组(P<0.05)。结论:科素亚联合卡托普利治疗心衰效果更佳。
作者 何涛 吴云
出处 《内蒙古医学杂志》 2007年第4期482-483,共2页 Inner Mongolia Medical Journal
  • 相关文献

参考文献4

  • 1陈国伟,郑忠锷.现代心脏内科学[M].长沙:湖南科学技术出版社,2003:624.
  • 2Cottone DC,Cysi LK,Pudra TO,et al.Change of plasma endothelin and growth factor levels,and of left ventricular mass,after chronic.AT1 receptor blockade in human hypertension[J].Am J Hypertension,2001,11(5):548.
  • 3史鲁秋,徐芳.抗心力衰竭药物的研究进展[J].中国药师,2003,6(7):406-408. 被引量:5
  • 4曾建新,黄干洪,徐志奇,谢干,毕健成,叶家骏.缬沙坦治疗慢性心力衰竭的疗效[J].中国现代医学杂志,2002,12(17):68-69. 被引量:5

二级参考文献24

  • 1Cadiotonic/Phosphodiesterase Inhibitor : OPC - 18 7 9 0 ( toborinone )[J]. Drugs of the Future, 1997, 20(12) : 1288.
  • 2MacGowan GA, Haber HL, Cowart TD, et al. Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis[J]. J Am Coll Cardiol, 1998, 31(6) : 1344-1351.
  • 3Anon. Phosphodiesterase Inhibitor: Toborinone[J]. Pharma. Projects: Therapeutic, 2002, Cardiostimulant a445.
  • 4Abraham WT, Lowes BD, White M, et al. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure[J]. J Card Fail, 1994,1(1) :57-62.
  • 5Changbin, Chang-Shen, Patrick, et al. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure [ J ]. Original Research,2001, 22(6) : 541-548.
  • 6Dingemanse J, Clozel M, Van Giersbergen PL. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist[J]. J Cardiovasc Pharmaco1,2002,39( 6 ) : 795-802.
  • 7Cotter G, Kiowski W, Kaluski E, et al. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrese in blood pressure in patients with congestive heart failure[J]. Eur J Heart Fail, 2001,3(4) : 457-461.
  • 8Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan,an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study[J]. Chest, 2002, 121(6) : 1860-1868.
  • 9Treatment of Pulmonary Hypertension/Antihypertensive/Endothelin ETA Antagonist: Sitax-sentan sodittrn(TBC-11251)[J]. Drugs of the Future, 2001,26(2) : 205.
  • 10Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure[J]. Circulation, 2001,103(18) : E94-4.

共引文献10

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部